Vaxcyte, Inc. reports clinical-stage vaccine developments focused on bacterial diseases, led by pneumococcal conjugate vaccine candidates in its PCV franchise. Recurring updates cover VAX-31 clinical studies in adult and infant populations, earlier PCV candidates including VAX-24 and VAX-XL, and pipeline programs such as VAX-A1 for Group A Strep and VAX-GI for Shigella.
Company news also addresses the XpressCF cell-free protein synthesis platform licensed from Sutro Biopharma, manufacturing and commercial-readiness activities, equity financings, quarterly financial results, and healthcare conference participation. These releases tie Vaxcyte’s vaccine engineering platform to clinical progress, supply-chain development, and capital resources supporting its pipeline.
Vaxcyte, a next-generation vaccine company, has successfully closed its initial public offering, issuing 17,968,750 shares at $16.00 each, including the full underwriter's option of 2,343,750 shares. This IPO raised $287.5 million in gross proceeds, facilitating the company's mission to develop innovative vaccines for serious infectious diseases. The shares began trading on Nasdaq under the ticker symbol 'PCVX' on June 12, 2020. Vaxcyte utilizes a cutting-edge protein synthesis platform to enhance vaccine development, focusing on pneumococcal conjugate vaccines and other novel therapies.